A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer By Ogkologos - November 21, 2025 360 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRADE study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Determining Fluid Requirements March 26, 2021 Blinatumomab Improves Survival in Children with Relapsed Leukemia April 1, 2021 EMA Recommends Granting a Marketing Authorisation for Enfortumab Vedotin for the... December 17, 2021 September 11, 2001 – Strength is Not Always Unyielding September 11, 2021 Load more HOT NEWS ¿Qué son los biosimilares para el tratamiento del cáncer? Husband Moved To Tears After Opening Christmas Gift From Wife Gentle regular exercise could reduce the risk of liver cancer in... Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Results in Greater EFS and pCR...
